Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cue Biopharma, Inc. stock logo
CUE
Cue Biopharma
$0.74
-1.8%
$0.72
$0.45
$1.99
$56.56M1.53510,205 shs211,023 shs
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
$4.00
$3.99
$0.72
$6.24
$258.25M2.27960,267 shsN/A
scPharmaceuticals, Inc. stock logo
SCPH
scPharmaceuticals
$5.17
+1.8%
$4.30
$1.94
$6.28
$268.18M0.4304,711 shs396,074 shs
Zhengye Biotechnology Holding Limited stock logo
ZYBT
Zhengye Biotechnology
$5.30
-4.2%
$6.63
$3.50
$14.30
$249.98MN/A41,863 shs8,867 shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cue Biopharma, Inc. stock logo
CUE
Cue Biopharma
-1.79%-16.50%+6.53%-2.05%-11.71%
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
0.00%0.00%0.00%+146.91%-31.03%
scPharmaceuticals, Inc. stock logo
SCPH
scPharmaceuticals
+1.77%-7.68%+27.97%+98.85%+2.78%
Zhengye Biotechnology Holding Limited stock logo
ZYBT
Zhengye Biotechnology
-4.16%-4.50%-10.47%-60.68%+529,999,900.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Cue Biopharma, Inc. stock logo
CUE
Cue Biopharma
3.8382 of 5 stars
3.54.00.04.70.00.80.6
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
2.1223 of 5 stars
4.20.00.00.00.02.50.0
scPharmaceuticals, Inc. stock logo
SCPH
scPharmaceuticals
3.8033 of 5 stars
3.52.00.04.21.41.70.6
Zhengye Biotechnology Holding Limited stock logo
ZYBT
Zhengye Biotechnology
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cue Biopharma, Inc. stock logo
CUE
Cue Biopharma
3.00
Buy$4.00442.59% Upside
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
2.44
Hold$11.75193.75% Upside
scPharmaceuticals, Inc. stock logo
SCPH
scPharmaceuticals
3.00
Buy$14.00170.79% Upside
Zhengye Biotechnology Holding Limited stock logo
ZYBT
Zhengye Biotechnology
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest CUE, ZYBT, SCPH, and INZY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/16/2025
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
5/16/2025
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
5/16/2025
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeModerate Buy ➝ Hold
5/16/2025
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Equal Weight$4.00
5/16/2025
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold$15.00 ➝ $4.00
5/14/2025
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$15.00 ➝ $12.00
(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cue Biopharma, Inc. stock logo
CUE
Cue Biopharma
$9.29M5.98N/AN/A$0.28 per share2.63
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
N/AN/AN/AN/A$0.90 per shareN/A
scPharmaceuticals, Inc. stock logo
SCPH
scPharmaceuticals
$36.33M7.51N/AN/A$0.27 per share19.15
Zhengye Biotechnology Holding Limited stock logo
ZYBT
Zhengye Biotechnology
$186.36M1.34$0.10 per share53.67$1.02 per share5.20
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cue Biopharma, Inc. stock logo
CUE
Cue Biopharma
-$40.67M-$0.67N/AN/AN/A-507.87%-228.43%-114.66%8/13/2025 (Estimated)
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
-$102.02M-$1.69N/AN/AN/AN/A-159.93%-82.48%8/5/2025 (Estimated)
scPharmaceuticals, Inc. stock logo
SCPH
scPharmaceuticals
-$85.15M-$1.91N/AN/AN/A-216.24%-594.07%-73.54%8/13/2025 (Estimated)
Zhengye Biotechnology Holding Limited stock logo
ZYBT
Zhengye Biotechnology
$1.55MN/A0.00N/AN/AN/AN/AN/A

Latest CUE, ZYBT, SCPH, and INZY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2025Q2 2025
Cue Biopharma, Inc. stock logo
CUE
Cue Biopharma
-$0.13N/AN/AN/A$2.00 millionN/A
8/13/2025Q2 2025
scPharmaceuticals, Inc. stock logo
SCPH
scPharmaceuticals
-$0.30N/AN/AN/A$15.41 millionN/A
8/5/2025Q2 2025
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
-$0.36N/AN/AN/AN/AN/A
5/14/2025Q1 2025
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
-$0.43-$0.44-$0.01-$0.44N/AN/A
5/14/2025Q1 2025
scPharmaceuticals, Inc. stock logo
SCPH
scPharmaceuticals
-$0.28-$0.34-$0.06-$0.37$11.63 million$11.75 million
5/12/2025Q1 2025
Cue Biopharma, Inc. stock logo
CUE
Cue Biopharma
-$0.14-$0.17-$0.03-$0.17$0.90 million$0.42 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cue Biopharma, Inc. stock logo
CUE
Cue Biopharma
N/AN/AN/AN/AN/A
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
N/AN/AN/AN/AN/A
scPharmaceuticals, Inc. stock logo
SCPH
scPharmaceuticals
N/AN/AN/AN/AN/A
Zhengye Biotechnology Holding Limited stock logo
ZYBT
Zhengye Biotechnology
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cue Biopharma, Inc. stock logo
CUE
Cue Biopharma
N/A
1.03
1.03
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
0.65
2.19
2.19
scPharmaceuticals, Inc. stock logo
SCPH
scPharmaceuticals
3.86
5.48
4.61
Zhengye Biotechnology Holding Limited stock logo
ZYBT
Zhengye Biotechnology
0.01
1.31
0.88

Institutional Ownership

CompanyInstitutional Ownership
Cue Biopharma, Inc. stock logo
CUE
Cue Biopharma
35.04%
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
88.30%
scPharmaceuticals, Inc. stock logo
SCPH
scPharmaceuticals
89.52%
Zhengye Biotechnology Holding Limited stock logo
ZYBT
Zhengye Biotechnology
N/A

Insider Ownership

CompanyInsider Ownership
Cue Biopharma, Inc. stock logo
CUE
Cue Biopharma
10.78%
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
12.18%
scPharmaceuticals, Inc. stock logo
SCPH
scPharmaceuticals
4.78%
Zhengye Biotechnology Holding Limited stock logo
ZYBT
Zhengye Biotechnology
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Cue Biopharma, Inc. stock logo
CUE
Cue Biopharma
6075.35 million67.23 millionOptionable
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
5064.56 million56.70 millionOptionable
scPharmaceuticals, Inc. stock logo
SCPH
scPharmaceuticals
3052.79 million50.27 millionOptionable
Zhengye Biotechnology Holding Limited stock logo
ZYBT
Zhengye Biotechnology
27847.17 millionN/AN/A

Recent News About These Companies

Zhengye Biotechnology Holding Ltd
ZYBT Zhengye Biotechnology Holding Limited
Zhengye Biotechnology Holding Ltd.
Zhengye Biotechnology Holding Limited (ZYBT)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Cue Biopharma stock logo

Cue Biopharma NASDAQ:CUE

$0.74 -0.01 (-1.79%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$0.74 +0.00 (+0.65%)
As of 08/1/2025 07:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.

Inozyme Pharma stock logo

Inozyme Pharma NASDAQ:INZY

$4.00 0.00 (0.00%)
As of 07/1/2025

Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

scPharmaceuticals stock logo

scPharmaceuticals NASDAQ:SCPH

$5.17 +0.09 (+1.77%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$5.18 +0.00 (+0.10%)
As of 08/1/2025 04:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX. The company's product pipeline also includes SCP-111 (furosemide injection), an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home; and SCP-111 Autoinjector, an investigational single-entity, drug-device combination product candidate consisting of a prefilled syringe containing SCP-111, preloaded into a commercially available, fixed single dose, disposable, two step mechanical autoinjector. It has a collaboration agreement with West Pharmaceutical Services, Inc. The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts.

Zhengye Biotechnology stock logo

Zhengye Biotechnology NASDAQ:ZYBT

$5.30 -0.23 (-4.16%)
As of 08/1/2025 04:00 PM Eastern

Zhengye Biotechnology Holding Limited is a veterinary vaccine manufacturer which encompasses research, development, manufacturing and sales of veterinary vaccines, with a focus on livestock vaccine principally in China. Zhengye Biotechnology Holding Limited is based in Jilin, China.